Shattuck Labs, Inc. (STTK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the STTK SEC filings page.
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue for fiscal year 2025, down 82.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The company remains development-stage: R&D-led operations run on external financing rather than commercial revenue.
In FY2025, the cash-and-earnings gap narrowed: net loss was-$48.8M while operating cash flow was-$39.9M , meaning accounting losses did not translate one-for-one into cash outflow. Free cash flow was-$40.0M despite only$71K of capital expenditures, showing that operating activity—not physical reinvestment—is consuming nearly all cash.
R&D was
FY2025 financing supplied
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Shattuck Labs, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Shattuck Labs, Inc. held $79.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $39.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Shattuck Labs, Inc. scores 49/100 among other emerging companies.
Shattuck Labs, Inc. had 72M shares outstanding at the end of fiscal year 2025, against 48M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Shattuck Labs, Inc. scores 32/100 among other emerging companies.
Shattuck Labs, Inc. spent $35.3M on research and development in fiscal year 2025, which was 67.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Shattuck Labs, Inc. scores 88/100 among other emerging companies.
Shattuck Labs, Inc. reported revenue of $1.0M in fiscal year 2025, against $5.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Shattuck Labs, Inc. scores 17/100 among other emerging companies.
Shattuck Labs, Inc.'s operations used $39.9M of cash in fiscal year 2025, against $60.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Shattuck Labs, Inc. scores 71/100 among other emerging companies.
Shattuck Labs, Inc.'s cash, cash equivalents and investments came to $79.1M at the end of fiscal year 2025, against $8.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Shattuck Labs, Inc. scores 96/100 among other emerging companies.
Shattuck Labs, Inc. scores 36.65, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($635.3M) relative to total liabilities ($8.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Shattuck Labs, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Shattuck Labs, Inc. reported a net loss of $48.8M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Shattuck Labs, Inc. generated $0 in revenue in Q2 2026.
Shattuck Labs, Inc.'s EBITDA was -$15.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.4% from the same quarter a year earlier. Against the prior quarter it is down 4.4%.
Shattuck Labs, Inc. reported -$15.2M in net income in Q2 2026. This represents a decrease of 21.6% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.
Shattuck Labs, Inc. earned -$0.12 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 7.7%.
Cash & Balance Sheet
Shattuck Labs, Inc. held $63.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Shattuck Labs, Inc.'s ROE was -7.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 14.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Shattuck Labs, Inc. invested $11.7M in research and development in Q2 2026. This represents an increase of 34.8% from the same quarter a year earlier. Against the prior quarter it is up 6.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
STTK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | N/A | $1.0M-66.6% | $0-100.0% | $0-100.0% | $0-100.0% | $3.0M+336.9% |
| R&D Expenses | $11.7M+34.8% | $10.9M+10.4% | N/A | $7.6M-53.3% | $8.7M-54.9% | $9.9M-39.0% | $15.4M+1.1% | $16.3M-32.6% |
| SG&A Expenses | $4.5M+2.4% | $4.6M+2.9% | N/A | $4.1M-11.0% | $4.4M-18.4% | $4.5M-8.7% | $4.2M-4.3% | $4.6M-9.2% |
| Operating Income | -$16.2M-24.0% | -$15.5M-8.0% | N/A | -$10.7M+40.2% | -$13.0M+43.2% | -$14.4M+28.2% | -$19.6M-3.6% | -$17.9M+37.3% |
| EBITDA | -$15.3M-26.4% | -$14.7M-8.9% | N/A | -$9.8M+42.2% | -$12.1M+45.0% | -$13.5M+29.5% | -$18.7M-4.0% | -$17.0M+38.5% |
| Net Income | -$15.2M-21.6% | -$14.8M-7.8% | N/A | -$10.1M+39.7% | -$12.5M+42.2% | -$13.7M+26.0% | -$18.7M-5.6% | -$16.7M+39.5% |
| EPS (Basic) | -$0.12+50.0% | -$0.13+51.9% | -$0.08+78.4% | -$0.14+57.6% | -$0.24+42.9% | -$0.27+27.0% | -$0.37+9.8% | -$0.33+49.2% |
| EPS (Diluted) | -$0.12 | -$0.13 | -$0.08+78.4% | -$0.14+57.6% | -$0.24+42.9% | -$0.27+27.0% | -$0.37+9.8% | -$0.33+49.2% |
| Diluted Shares (Avg) | 130M | 112M | N/A | 72M+42.0% | 51M+0.4% | 51M+0.8% | N/A | 51M+19.7% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
STTK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $220.7M+242.8% | $102.1M+32.3% | $91.0M0.0% | $100.3M-10.2% | $64.4M-50.0% | $77.2M-47.3% | $91.0M-42.9% | $111.7M-14.4% |
| Current Assets | $213.3M+290.1% | $93.8M+41.2% | $82.5M+4.1% | $90.7M-8.1% | $54.7M-52.2% | $66.4M-49.3% | $79.2M-44.7% | $98.7M-12.6% |
| Cash & Equivalents | $63.3M+25.4% | $90.4M+48.5% | $54.2M-5.6% | $42.5M-2.9% | $50.5M-16.8% | $60.9M-19.9% | $57.4M-54.3% | $43.8M+7.9% |
| Short-Term Investments | $145.0M | $0 | $23.9M+53.0% | $43.6M-5.7% | $0-100.0% | $0-100.0% | $15.6M+212.1% | $46.2M-23.5% |
| Long-Term Investments | $1.0M | $1.0M | $1.0M | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $9.5M+29.6% | $6.3M-34.4% | $8.6M-24.4% | $7.1M-53.2% | $7.4M-59.2% | $9.6M-45.3% | $11.4M-23.1% | $15.1M-14.3% |
| Current Liabilities | $7.7M+44.9% | $4.2M-41.9% | $7.1M-20.9% | $5.3M-57.0% | $5.3M-64.5% | $7.3M-48.9% | $8.9M-22.1% | $12.4M-11.8% |
| Non-Current Liabilities | $1.8M-10.7% | $2.0M-10.1% | $1.6M-36.8% | $1.8M-35.9% | $2.0M-32.2% | $2.3M-29.0% | $2.5M-26.4% | $2.7M-24.1% |
| Total Equity | $211.1M+270.3% | $95.8M+41.8% | $82.4M+3.5% | $93.2M-3.5% | $57.0M-48.5% | $67.6M-47.5% | $79.6M-45.0% | $96.6M-14.4% |
| Retained Earnings | -$460.4M-12.9% | -$445.3M-12.6% | -$430.5M-12.8% | -$417.9M-15.1% | -$407.9M-17.8% | -$395.4M-21.7% | -$381.7M-24.6% | -$363.0M-25.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
STTK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M+2.4% | -$13.4M-11.6% | -$8.5M+51.1% | -$8.9M+44.4% | -$10.4M+4.5% | -$12.0M+25.5% | -$17.4M+10.6% | -$16.1M+4.0% |
| Depreciation & Amortization | $851K-8.4% | $891K-4.8% | N/A | $917K-3.8% | $929K-3.4% | $936K-3.9% | $911K-3.0% | $953K-6.6% |
| Stock-Based Compensation | $2.7M+44.6% | $2.4M+40.3% | N/A | $1.8M-30.4% | $1.9M-29.1% | $1.7M-30.5% | N/A | $2.6M+44.9% |
| Capital Expenditures | N/A | N/A | $0 | $71K+69.0% | N/A | N/A | $0-100.0% | $42K+121.1% |
| Free Cash Flow | N/A | N/A | -$8.5M+51.1% | -$9.0M+44.1% | N/A | N/A | -$17.4M+10.6% | -$16.1M+3.8% |
| Investing Cash Flow | -$144.9M | $23.8M+52.9% | $20.0M-35.5% | -$43.5M-5196.8% | $0+100.0% | $15.6M+146.9% | $31.0M-44.5% | -$821K+94.4% |
| Financing Cash Flow | $128.0M | $25.8M+45368.4% | $134K+286.1% | $44.5M+193365.2% | $0-100.0% | -$57K+69.0% | -$72K-100.1% | $23K+9.5% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
STTK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | -1071.6% | N/A | N/A | N/A | -597.9% |
| Net Margin | N/A | N/A | N/A | -1005.6% | N/A | N/A | N/A | -556.4% |
| Return on Equity | -7.2%+14.7pp | -15.4%+4.9pp | N/A | -10.8%+6.5pp | -21.9%-2.4pp | -20.3%-5.9pp | -23.5%-11.2pp | -17.3%+7.2pp |
| Return on Assets | -6.9%+12.5pp | -14.5%+3.3pp | N/A | -10.0%+4.9pp | -19.4%-2.6pp | -17.8%-5.1pp | -20.5%-9.4pp | -14.9%+6.2pp |
| Current Ratio | 27.59+17.3x | 22.06+13.0x | 11.70+2.8x | 17.00+9.0x | 10.25+2.6x | 9.08-0.1x | 8.88-3.6x | 7.96-0.1x |
| Debt-to-Equity | 0.05-0.1x | 0.07-0.1x | 0.100.0x | 0.08-0.1x | 0.130.0x | 0.140.0x | 0.140.0x | 0.160.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | 0.010.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.030.0x |
| FCF Margin | N/A | N/A | N/A | -900.0% | N/A | N/A | N/A | -537.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Shattuck Labs, Inc. STTK | FY2025 | $1.0M | -$48.8M | N/A | $635.3M | 59/100 |
| Inflarx IFRX | FY2025 | $20K | N/A | N/A | $319.8M | — |
| Macrogenics Inc MGNX | FY2025 | $149.5M | -$75K | -0.1% | $275.2M | 56/100 |
| Surrozen Inc SRZN | FY2025 | $3.5M | -$242.0M | N/A | $243.1M | 42/100 |
| Anixa Biosciences Inc ANIX | FY2025 | N/A | -$10.9M | N/A | $98.7M | — |
| Atara Biotherape ATRA | FY2025 | $120.8M | $32.7M | 27.1% | $102.7M | 63/100 |
Where Shattuck Labs, Inc. Ranks
Frequently Asked Questions
What is Shattuck Labs, Inc.'s annual revenue?
Shattuck Labs, Inc. (STTK) reported $1.0M in total revenue for fiscal year 2025. This represents a -82.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Shattuck Labs, Inc.'s revenue growing?
Shattuck Labs, Inc. (STTK) revenue declined by 82.5% year-over-year, from $5.7M to $1.0M in fiscal year 2025.
Is Shattuck Labs, Inc. profitable?
No, Shattuck Labs, Inc. (STTK) reported a net income of -$48.8M in fiscal year 2025.
What is Shattuck Labs, Inc.'s EBITDA?
Shattuck Labs, Inc. (STTK) had EBITDA of -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Shattuck Labs, Inc.'s return on equity (ROE)?
Shattuck Labs, Inc. (STTK) has a return on equity of -59.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Shattuck Labs, Inc.'s free cash flow?
Shattuck Labs, Inc. (STTK) recorded an outflow of $40.0M in free cash flow during fiscal year 2025. This represents a 34.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Shattuck Labs, Inc.'s operating cash flow?
Shattuck Labs, Inc. (STTK) recorded an outflow of $39.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Shattuck Labs, Inc.'s total assets?
Shattuck Labs, Inc. (STTK) had $91.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Shattuck Labs, Inc.'s capital expenditures?
Shattuck Labs, Inc. (STTK) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Shattuck Labs, Inc. spend on research and development?
Shattuck Labs, Inc. (STTK) invested $35.3M in research and development during fiscal year 2025.
What is Shattuck Labs, Inc.'s current ratio?
Shattuck Labs, Inc. (STTK) had a current ratio of 11.70 as of fiscal year 2025, which is generally considered healthy.
What is Shattuck Labs, Inc.'s debt-to-equity ratio?
Shattuck Labs, Inc. (STTK) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Shattuck Labs, Inc.'s return on assets (ROA)?
Shattuck Labs, Inc. (STTK) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Shattuck Labs, Inc.'s P/E ratio?
Shattuck Labs, Inc. (STTK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $635.3M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Shattuck Labs, Inc.'s price-to-sales ratio?
Shattuck Labs, Inc. (STTK) trades at 635x sales, its market capitalization divided by revenue of $1.0M revenue, FY2025. The market capitalization is $635.3M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Shattuck Labs, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Shattuck Labs, Inc. (STTK) held $79.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Shattuck Labs, Inc.'s Altman Z-Score?
Shattuck Labs, Inc. (STTK) has an Altman Z-Score of 36.65, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Shattuck Labs, Inc.'s Piotroski F-Score?
Shattuck Labs, Inc. (STTK) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Shattuck Labs, Inc.'s earnings high quality?
Shattuck Labs, Inc. (STTK) reported a net loss of $48.8M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Shattuck Labs, Inc.?
Shattuck Labs, Inc. (STTK) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.